The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Intraveno (IV) Iron Drugs Market Research Report 2025
Synopsis
Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal absorption, and non-compliance.
The global Intraveno (IV) Iron Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Intraveno (IV) Iron Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intraveno (IV) Iron Drugs.
Report Scope
The Intraveno (IV) Iron Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Intraveno (IV) Iron Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Intraveno (IV) Iron Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
AMAG Pharmaceuticals
Galenica
Actavis
American Regent
Sanofi
Luitpold Pharmaceuticals
Fresenius Medical Care
Pharmacosmos
Vifor Pharma
Segment by Type
Low Molecular Weight Iron Dextran
Ferric Gluconate
Iron Sucrose
Ferric Carboxyl Maltose
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Intraveno (IV) Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Intraveno (IV) Iron Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal absorption, and non-compliance.
The global Intraveno (IV) Iron Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Intraveno (IV) Iron Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intraveno (IV) Iron Drugs.
Report Scope
The Intraveno (IV) Iron Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Intraveno (IV) Iron Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Intraveno (IV) Iron Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
AMAG Pharmaceuticals
Galenica
Actavis
American Regent
Sanofi
Luitpold Pharmaceuticals
Fresenius Medical Care
Pharmacosmos
Vifor Pharma
Segment by Type
Low Molecular Weight Iron Dextran
Ferric Gluconate
Iron Sucrose
Ferric Carboxyl Maltose
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Intraveno (IV) Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Intraveno (IV) Iron Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Intraveno (IV) Iron Drugs Market Overview
1.1 Product Overview and Scope of Intraveno (IV) Iron Drugs
1.2 Intraveno (IV) Iron Drugs Segment by Type
1.2.1 Global Intraveno (IV) Iron Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Low Molecular Weight Iron Dextran
1.2.3 Ferric Gluconate
1.2.4 Iron Sucrose
1.2.5 Ferric Carboxyl Maltose
1.3 Intraveno (IV) Iron Drugs Segment by Application
1.3.1 Global Intraveno (IV) Iron Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Global Intraveno (IV) Iron Drugs Market Size Estimates and Forecasts
1.4.1 Global Intraveno (IV) Iron Drugs Revenue 2019-2030
1.4.2 Global Intraveno (IV) Iron Drugs Sales 2019-2030
1.4.3 Global Intraveno (IV) Iron Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Intraveno (IV) Iron Drugs Market Competition by Manufacturers
2.1 Global Intraveno (IV) Iron Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Intraveno (IV) Iron Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Intraveno (IV) Iron Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Intraveno (IV) Iron Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Intraveno (IV) Iron Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Intraveno (IV) Iron Drugs, Product Type & Application
2.7 Intraveno (IV) Iron Drugs Market Competitive Situation and Trends
2.7.1 Intraveno (IV) Iron Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Intraveno (IV) Iron Drugs Players Market Share by Revenue
2.7.3 Global Intraveno (IV) Iron Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Intraveno (IV) Iron Drugs Retrospective Market Scenario by Region
3.1 Global Intraveno (IV) Iron Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Intraveno (IV) Iron Drugs Global Intraveno (IV) Iron Drugs Sales by Region: 2019-2030
3.2.1 Global Intraveno (IV) Iron Drugs Sales by Region: 2019-2024
3.2.2 Global Intraveno (IV) Iron Drugs Sales by Region: 2025-2030
3.3 Global Intraveno (IV) Iron Drugs Global Intraveno (IV) Iron Drugs Revenue by Region: 2019-2030
3.3.1 Global Intraveno (IV) Iron Drugs Revenue by Region: 2019-2024
3.3.2 Global Intraveno (IV) Iron Drugs Revenue by Region: 2025-2030
3.4 North America Intraveno (IV) Iron Drugs Market Facts & Figures by Country
3.4.1 North America Intraveno (IV) Iron Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Intraveno (IV) Iron Drugs Sales by Country (2019-2030)
3.4.3 North America Intraveno (IV) Iron Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Intraveno (IV) Iron Drugs Market Facts & Figures by Country
3.5.1 Europe Intraveno (IV) Iron Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Intraveno (IV) Iron Drugs Sales by Country (2019-2030)
3.5.3 Europe Intraveno (IV) Iron Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Intraveno (IV) Iron Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Intraveno (IV) Iron Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Intraveno (IV) Iron Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Intraveno (IV) Iron Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Intraveno (IV) Iron Drugs Market Facts & Figures by Country
3.7.1 Latin America Intraveno (IV) Iron Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Intraveno (IV) Iron Drugs Sales by Country (2019-2030)
3.7.3 Latin America Intraveno (IV) Iron Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Intraveno (IV) Iron Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Intraveno (IV) Iron Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Intraveno (IV) Iron Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Intraveno (IV) Iron Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Intraveno (IV) Iron Drugs Sales by Type (2019-2030)
4.1.1 Global Intraveno (IV) Iron Drugs Sales by Type (2019-2024)
4.1.2 Global Intraveno (IV) Iron Drugs Sales by Type (2025-2030)
4.1.3 Global Intraveno (IV) Iron Drugs Sales Market Share by Type (2019-2030)
4.2 Global Intraveno (IV) Iron Drugs Revenue by Type (2019-2030)
4.2.1 Global Intraveno (IV) Iron Drugs Revenue by Type (2019-2024)
4.2.2 Global Intraveno (IV) Iron Drugs Revenue by Type (2025-2030)
4.2.3 Global Intraveno (IV) Iron Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Intraveno (IV) Iron Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Intraveno (IV) Iron Drugs Sales by Application (2019-2030)
5.1.1 Global Intraveno (IV) Iron Drugs Sales by Application (2019-2024)
5.1.2 Global Intraveno (IV) Iron Drugs Sales by Application (2025-2030)
5.1.3 Global Intraveno (IV) Iron Drugs Sales Market Share by Application (2019-2030)
5.2 Global Intraveno (IV) Iron Drugs Revenue by Application (2019-2030)
5.2.1 Global Intraveno (IV) Iron Drugs Revenue by Application (2019-2024)
5.2.2 Global Intraveno (IV) Iron Drugs Revenue by Application (2025-2030)
5.2.3 Global Intraveno (IV) Iron Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Intraveno (IV) Iron Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Corporation Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Allergan Intraveno (IV) Iron Drugs Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 AMAG Pharmaceuticals
6.2.1 AMAG Pharmaceuticals Corporation Information
6.2.2 AMAG Pharmaceuticals Description and Business Overview
6.2.3 AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio
6.2.5 AMAG Pharmaceuticals Recent Developments/Updates
6.3 Galenica
6.3.1 Galenica Corporation Information
6.3.2 Galenica Description and Business Overview
6.3.3 Galenica Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Galenica Intraveno (IV) Iron Drugs Product Portfolio
6.3.5 Galenica Recent Developments/Updates
6.4 Actavis
6.4.1 Actavis Corporation Information
6.4.2 Actavis Description and Business Overview
6.4.3 Actavis Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Actavis Intraveno (IV) Iron Drugs Product Portfolio
6.4.5 Actavis Recent Developments/Updates
6.5 American Regent
6.5.1 American Regent Corporation Information
6.5.2 American Regent Description and Business Overview
6.5.3 American Regent Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 American Regent Intraveno (IV) Iron Drugs Product Portfolio
6.5.5 American Regent Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi Intraveno (IV) Iron Drugs Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Luitpold Pharmaceuticals
6.6.1 Luitpold Pharmaceuticals Corporation Information
6.6.2 Luitpold Pharmaceuticals Description and Business Overview
6.6.3 Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio
6.7.5 Luitpold Pharmaceuticals Recent Developments/Updates
6.8 Fresenius Medical Care
6.8.1 Fresenius Medical Care Corporation Information
6.8.2 Fresenius Medical Care Description and Business Overview
6.8.3 Fresenius Medical Care Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Fresenius Medical Care Intraveno (IV) Iron Drugs Product Portfolio
6.8.5 Fresenius Medical Care Recent Developments/Updates
6.9 Pharmacosmos
6.9.1 Pharmacosmos Corporation Information
6.9.2 Pharmacosmos Description and Business Overview
6.9.3 Pharmacosmos Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pharmacosmos Intraveno (IV) Iron Drugs Product Portfolio
6.9.5 Pharmacosmos Recent Developments/Updates
6.10 Vifor Pharma
6.10.1 Vifor Pharma Corporation Information
6.10.2 Vifor Pharma Description and Business Overview
6.10.3 Vifor Pharma Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Vifor Pharma Intraveno (IV) Iron Drugs Product Portfolio
6.10.5 Vifor Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Intraveno (IV) Iron Drugs Industry Chain Analysis
7.2 Intraveno (IV) Iron Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Intraveno (IV) Iron Drugs Production Mode & Process
7.4 Intraveno (IV) Iron Drugs Sales and Marketing
7.4.1 Intraveno (IV) Iron Drugs Sales Channels
7.4.2 Intraveno (IV) Iron Drugs Distributors
7.5 Intraveno (IV) Iron Drugs Customers
8 Intraveno (IV) Iron Drugs Market Dynamics
8.1 Intraveno (IV) Iron Drugs Industry Trends
8.2 Intraveno (IV) Iron Drugs Market Drivers
8.3 Intraveno (IV) Iron Drugs Market Challenges
8.4 Intraveno (IV) Iron Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
